Shareholders Reject Executive Compensation, Show High Dissent for Board Members at Annual Meeting
Summary
TG Therapeutics shareholders rejected the advisory vote on executive compensation and showed significant dissent for certain board members at the 2026 Annual Meeting, highlighting a governance challenge despite recent positive operational news.
Key Events
-
Executive Compensation Rejected
Shareholders voted against the advisory proposal to approve the compensation of named executive officers, with 48,858,169 votes against compared to 31,905,837 for. This follows a previous proxy statement indicating low approval for 2025 executive compensation.
-
Significant Dissent for Board Members
While all six directors were re-elected, two board members, Kenneth Hoberman and Sagar Lonial, MD, received high 'withheld' votes of 34.48% and 45.15% respectively, indicating notable shareholder dissatisfaction with their positions.
-
Auditor Ratification Approved
KPMG LLP was ratified as the independent registered public accounting firm for 2026 with overwhelming support, receiving 112,329,330 votes for.
Analysis
Shareholders rejected the advisory vote on executive compensation, indicating significant dissatisfaction with the company's pay practices. This outcome, coupled with substantial 'withheld' votes for two directors, signals a notable governance challenge for the board and management. This is particularly striking given the company's recent strong operational performance and positive clinical trial results, suggesting a disconnect between shareholder sentiment on governance and the company's business momentum. The board will likely face pressure to address these concerns.
At the time of this filing, TGTX was trading at $49.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.6B. The 52-week trading range was $25.28 to $50.41. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.